Kiniksa Pharmaceuticals International (KNSA) Cash & Current Investments (2017 - 2026)

Kiniksa Pharmaceuticals International's Cash & Current Investments history runs 10 years deep, the most recent figure standing at $468.1 million for Q1 2026.

• Quarterly Cash & Current Investments rose 23.33% year-over-year to $468.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $468.1 million (up 23.33% YoY) and the FY2025 annual result came in at $414.1 million, up 69.96% from the prior year.
• Cash & Current Investments was $468.1 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $414.1 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $529.3 million in Q3 2025 and bottomed at $80.6 million in Q1 2023.
• A 5-year average of $279.3 million and a median of $243.6 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments plunged 58.25% — and 2024, when it surged 164.89%.
• Kiniksa Pharmaceuticals International's Cash & Current Investments stood at $190.6 million in 2022, then gained by 8.27% to $206.4 million in 2023, then gained by 18.05% to $243.6 million in 2024, then jumped by 69.96% to $414.1 million in 2025, then advanced by 13.05% to $468.1 million in 2026.
• Business Quant data shows KNSA's Cash & Current Investments at $468.1 million in Q1 2026, $414.1 million in Q4 2025, and $529.3 million in Q3 2025.